Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herceptin sBLA (correction)

Executive Summary

Roche/Genentech submitted a supplemental BLA for Herceptin for adjuvant treatment of early stage HER2-positive breast cancer in the first quarter and plan to file an sBLA for HER2-positive advanced gastric cancer in 2008; "The Pink Sheet" incorrectly reported that trastuzumabwas also under review for first-line, non-squamous non-small cell lung cancer (1"The Pink Sheet" June 26, 2006, p. 17). The firms' Avastin has an sBLA pending for that use...

You may also be interested in...



Roche To Build On Pharma, Diagnostics Expertise For Personalized Medicine

Roche sees its capabilities with both drug and diagnostics development as the key to maintaining a leadership position in targeted oncologics and personalized medicine

OTC Sales Of Hearing Aids In US For Mild To Moderate Loss Allowed Under FDA Final Rule

After requirement from Congress and push from President Biden, FDA establishes regulatory category for hearing aids to allow US consumers with mild to moderate hearing loss to purchase the devices without a prescription or prior exam.

Safe Use Of Hydrogen-Peroxide Contact Lens Solution Magnified in US FDA Draft Guidance

Draft guidance pulls from Ophthalmic Devices Panel and Risk Communication Advisory Committee 2017 meeting to discuss more clearly communicating risks of the solutions to consumers while allowing products to remain available OTC.

Latest News
See All
UsernamePublicRestriction

Register

PS047340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel